Skip to main content
. 2022 Jul 28;13(Suppl 4):45–56. doi: 10.6004/jadpro.2022.13.5.14

Table 3. Waldenström Macroglobulinemia–Related Complications.

Complication Pathophysiology Exam findings Diagnostic findings
Cold agglutin anemia (occurs in 10% of WM patients)
  • IgM binds to I antigen on surface of red blood cells. This binding results in hemolysis causing anemia.

  • Raynaud symptoms

  • Cold agglutinin titer > 1:64

  • Anemia

  • Elevated LDH

  • Indirect hyperbilirubinemia

  • Positive compliment

Cryoglobulinemia (occurs in 10%–20% of WM patients)
  • Immunoglobulins precipitate with temperatures less than 37°C forming capillary globs resulting in impaired circulation.

  • Three types:
    • Type 1: monoclonal immunoglobulin to monoclonal immunoglobulin
    • Type 2: polyclonal Ig binds to monoclonal Ig resulting in immune complexes
    • Type 3: polyclonal Ig binds to polyclonal Ig resulting in immune complexes
  • Palpable purpura

  • Raynaud symptoms

  • Mucosal bleeding

  • Increased creatinine if developing glomerulonephritis

Hyperviscosity
  • The IgM immunoglobulin is a large pentameric molecule with half in the intravascular space. At increased levels, the IgM increases the plasma volume.

  • Fatigue

  • Vision changes

  • Bleeding

  • Headaches

  • Dizziness

  • Strokes

  • Monitor patients carefully during blood transfusion as the volume expansion may result in heart failure.

  • Retinal vein hemorrhages or engorgement

  • Increase viscosity level (> 4 CP)

Neuropathy (occurs in 30%–50% of patients with a monoclonal IgM and 20% in WM patients)
  • The monoclonal IgM binds to the MAG on the surface of the myelin sheath.

  • Numbness, ataxia, painful neuropathy

  • Elevated anti MAG level > 20000 BTU/mL

  • EMG reveals a demyelinating neuropathy

  • Evaluate for other causes of neuropathy, including VEGF level, MRI spine, and antiganglioside antibodies

Note. LDH = lactate dehydrogenase; MAG = myelin-associated glycoprotein; EMG = electromyography; VEGF = vascular endothelial growth factor. Information from Bloch & Maki (1973); D'Sa et al. (2017); Desbois et al. (2019); Dimoupolis et al. (2000); Gertz (2018, 2019).